Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - Supply Chains Pose Risks To Drugmaker Revenues - MAR 2017

Americas February 2017 / Argentina / Industry

Drug shortages in Argentina are a potential risk for both pharmaceutical companies and the public's health. For example, on a regional basis, tuberculosis is not a significant problem in Argentina; however, supply chain issues may exacerbate the impact of the disease. Systemic drug shortages would compromise the ideals set out in President Macri's universal healthcare plan, although government action is likely to prevent serious disruption.


Industry Trend Analysis - Failure To Ratify TPP To Be A Loss For Innovative Pharmaceutical Firms - MAR 2017

Asia February 2017 / Asia / Industry

A failure to ratify the Trans-Pacific Partnership (TPP) will be a negative for multinational drugmakers operating in the Asia Pacific. With seven of the 12 participating members in the APAC region, collectively accounting for 42% of the region's medicine sales in 2016, the trade deal would have altered the landscape by introducing stronger intellectual property protection among other measures. We now expect improvements to member regulatory regimes to be more gradual, with alternatives to the TPP unlikely to result in a similarly significant improvement. This creates an environment that will be beneficial for generic drugmakers, allowing firms to tap on the rising demand for low-cost drugs among participating countries in Asia.


Industry Trend Analysis - Czech Republic - Q2 2017 - MAR 2017

Emerging Europe February 2017 / Czech Republic / Industry

Although most innovative drugmakers are present in the Czech market, their manufacturing presence is limited. The vast majority of multinationals import drugs for retail, with a small number of manufacturers, such as GlaxoSmithKline, licensing production to local companies. The Czech Republic has been a challenging market for businesses involved within the production, distribution and retailing of pharmaceutical goods in recent years. The impact of the eurozone recession, anaemic macroeconomic activity and reconciling healthcare spending with affordability has applied significant pressure to market participants. Given the high-value nature of innovative and patented drugs, sales have shifted towards the low-value generic medicines.


Industry Trend Analysis - Medicine Price Rise To Provide Some Relief For Drugmakers - MAR 2017

Middle East & Africa February 2017 / Egypt / Industry

Egyptian drugmakers will be given a boost as measures to raise the price of a number of essential medicines are imposed by the Ministry of Health. The agreement to include chronic disease treatments within the basket of drugs set for price increases has important implications for the population's access to long-term illness medications. Over the long-term, Egypt's medicine supply remains precarious, however, as conflicting interests between local drugmakers, distributors, patients and the Ministry of Health remain firm.


Industry Trend Analysis - Takeda Investment Highlights Growing Confidence In TiGenix - MAR 2017

Western Europe February 2017 / Belgium / Industry

Takeda's equity investment in TiGenix, coinciding with a recent US IPO, highlights a growing confidence in TiGenix and its lead product, Cx601, for treating complex perianal fistulas in Crohn's disease. Although Cx601 has yet to be commercialised, and TiGenix has yet to make a profit, development of the drug is progressing smoothly. Should Cx601 be approved and launched in the US and the EU, it will be poised to become a blockbuster drug filling an underserved niche.